REALiTY: REmoving Allergens with pLasma TechnologY

利用该奖项，将开发一种颠覆性的技术解决方案，以减轻英国数百万人的痛苦。据设想，开发的设备将部署在全国各地的家庭和办公室，以显着降低室内环境中空气中过敏原的浓度;从而为英国超过1200万过敏患者的整体健康做出重大贡献。这种颠覆性的技术解决方案将减轻过敏症对英国经济的负担，通过生产力损失估计每年约为71亿英镑，通过使用NHS资源估计每年约为3.11亿英镑。该项目建议开发冷大气压等离子体（CAP）该解决方案能够同时靶向多种变应原并克服与当前方法相关的许多缺点。为了确保广泛采用，从而最大限度地发挥这项研究的影响，开发的技术将被包装成一种低成本和节能的消费电器，适合在家庭中连续使用。技术发展不会是轻而易举的，也不会没有风险;然而，克服这些挑战的回报将是公共卫生和英国繁荣的大幅改善。为了取得成功，多个RCUK资助的研究项目的成果将汇集在一起，形成一个独特的工程解决方案，该解决方案将与一个具有前瞻性的英国工业合作伙伴共同开发。

Using this award a disruptive technological solution will be developed to alleviate the suffering of millions of people across the UK. It is envisaged that the developed device will be deployed in households and offices across the country to significantly reduce the concentration of airborne allergenic agents from within the indoor environment; thus making a significant contribution to the general wellbeing of over 12 million allergy sufferers in the UK. This disruptive technological solution will reduce the burden of allergy on the UK economy, which is estimated at around £7.1 Bn per annum through lost productivity and a further £311 million per year through the use of NHS resources.The project proposes the development of a Cold Atmospheric pressure Plasma (CAP) solution that is capable of simultaneously targeting multiple allergenic agents and overcomes many of the drawbacks associated with current approaches. To ensure widespread uptake and therefore maximise the impact from this research, the developed technology will be packaged as a low-cost and energy efficient consumer appliance, suitable for continuous use within the home. Technological development will not be easy nor risk free; however, the reward for overcoming these challenges will be a substantial improvement in public health and UK prosperity. To succeed, the outcomes of multiple RCUK funded research projects will be brought together to form a unique engineering solution which will be co-developed in collaboration with a forward-thinking UK-based industrial partner.